Tools
Stock profile

AMGEN INC (AMGN)

AMGN · Latest close $443.89 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$443.89
As of Nov 18, 2026
Tracked funds holding
6 of 149
2026 Q2 13F filings
Opened / added
0 / 2
vs previous quarter
Trimmed / exited
6
vs previous quarter

AMGEN INC (AMGN) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds adding and 6 funds trimming or exiting versus the previous quarter. 1 member of Congress reported 2 purchases vs 6 sales. Latest close $443.89 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Congress
2 buys vs 6 sales
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Matrix Asset Advisors · Torray Investment Partners LLC · Sarasin & Partners — 6 tracked funds hold AMGN. See all holders.

Insider and Congress activity

1 member of Congress reported buying (2 purchases vs 6 sales). Latest buy: Sep 22, 2026. Politician trading

Often held alongside

ISHARES RUSSELL 2000 ETF (IWM) · TARGET CORP (TGT) · GILEAD SCIENCES, INC. (GILD) · ISHARES RUSSELL 1000 GROWTH (IWF) · L3HARRIS TECHNOLOGIES, INC. /DE/ (LHX) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Matrix Asset Advisors3.03%102,817ADDED (+3.0%) Q3 filed Oct 13
Torray Investment Partners LLC2.92%59,771ADDED (+10.7%) Q3 filed Oct 30
Sarasin & Partners1.46%343,948TRIMMED (-48.4%) Q3 filed Oct 13
Mairs & Power Funds0.02%4,924TRIMMED (-0.8%) Q3 filed Nov 16
Atalanta Sosnoff Capital0.01%863TRIMMED (-11.8%) Q3 filed Nov 10
Dodge & Cox Funds<0.01%12,817TRIMMED (-4.1%) Q3 filed Nov 13
Check Capital Management——EXITED
OrbiMed Advisors——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +26.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

478.48249.792024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

152016Q3: 15 funds2016Q32016Q3

Tracked funds holding this stock, by quarter (2016Q3–2016Q3, 1 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.

All institutions · Form 13F

Institutions holding3,157 of 8,857 filers
Long-only filers among them3,145
Change vs 2026 Q1+50 net · 2,012 entered · 1,962 exited
Shares reported, all filers442,059,192
Reported value, all filers$159.3B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2025$36.8B
Net income · FY2025$7.7B
Total assets · FY2025$90.6B
Shares outstanding540,632,005
Market cap (at latest close)$240.0B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 30, 2026.

Short interest

Shares short · Oct 15, 202613,378,638
Share of shares outstanding2.47%
Days to cover4.97

Shares short at recent settlements — Jul 31, 2026: 13.3M · Aug 14, 2026: 12.0M · Aug 31, 2026: 13.0M · Sep 15, 2026: 14.1M · Sep 30, 2026: 14.0M · Oct 15, 2026: 13.4M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 30, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 2K · Aug 14, 2026: 144 · Aug 31, 2026: 4K · Sep 15, 2026: 0 · Sep 30, 2026: 9K · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 30, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 13, 2026Khosla RachnaOfficer1,252$516.8KAug 13, 2026SEC filing
Aug 11, 2026Khosla RachnaOfficer2,000$828.4KAug 11, 2026SEC filing
Aug 6, 2026Grygiel Nancy A.Officer2,970$1.2MAug 6, 2026SEC filing
Aug 6, 2026Grygiel Nancy A.Officer2,670$1.2MAug 6, 2026SEC filing
Aug 6, 2026Derek MillerOfficer3,890$1.6MAug 6, 2026SEC filing
May 4, 2026Grygiel Nancy A.Officer1,237$400.4KMay 4, 2026SEC filing
Feb 27, 2026Santos EstebanAssociate54,792$20.8MFeb 26, 2026SEC filing
Feb 19, 2026Busch Matthew C.ASSOCIATED TO AFFILIATE1,000$375.0KFeb 19, 2026SEC filing
Nov 20, 2025Grygiel Nancy A.Officer3,139$1.1MNov 20, 2025SEC filing
Nov 12, 2025Khosla RachnaOfficer890$300.3KNov 12, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 14, 2026Capital World InvestorsSC 13G29,596,1195.5%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G40,510,4847.5%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Sep 8, 2025The Vanguard GroupSC 13G/A53,860,79510.0%Aug 29, 2025SEC filing
Apr 17, 2025BlackRock, Inc.SC 13G/A40,830,8307.6%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

1 member of Congress reported buying (2 purchases vs 6 sales). Bought by Republicans. Latest buy: Sep 22, 2026.

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Taylor, David J.HouseR24Nov 3, 2026$1,001 - $15,000
Whitehouse, SheldonSenateD01Aug 12, 2026$1,001 - 15,000
Salazar, Maria ElviraHouseR01Apr 17, 2026$15,001 - $50,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 1,762 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Medicare/Medicaid (988), Health Issues (880), Taxation/Internal Revenue Code (427).

Federal contracts: $507.5M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$137.1K
FY2022$292.7M
FY2023$212.3M
FY2024$128.7K
FY2025$2.3M
FY2026$0

Largest awards collected

Award IDAgencyAmountStart
75A50118F33004Department of Health and Human Services$154.4MSep 13, 2018
75A50119C00061Department of Health and Human Services$26.4MSep 26, 2019
75A50123C00040Department of Health and Human Services$7.3MAug 28, 2023
36C24521F0279Department of Veterans Affairs$74.7KApr 9, 2021
15B61421FWB110130Department of Justice$10.8KMar 31, 2021

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Politicians

· Bought by Members — Last 6 months: bought by a member of the U.S. Congress

Financial Screens

· Buffett — Companies with high ROE sustained for more than a decade

· Growth — Revenue up every year for 5 straight years

· Dividend Growth — Dividends raised for more than 10 years

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Earnings Stability — Small earnings swings and almost no loss years

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Buffett — Latest ROE: 89.1% · Years ROE ≥15% (of 10): 9 · 10-yr avg ROE: 79.2% · Latest net income: $7.7B

· Growth — Latest revenue: $36.8B · 5-yr revenue CAGR: 7.6% · Straight growth years: 6

· Dividend Growth — Dividend per share: 9.66 · Dividend yield: 2.1% · Straight dividend years: 10 · 10-yr dividend growth: 132.8%

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.79 · Operating cash flow: $10.0B · Net income: $7.7B

· Earnings Stability — Earnings variation (CV): 0.29 · Loss years (of 10): 0 · Latest net income: $7.7B

· Bought by Members — Members buying: 1 · Buy txns: 2 · Sell txns: 6 · Latest buy: Sep 22, 2026

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Super-investor 13F BEST — appeared in 1 of the last 40 quarterly lists; latest 2016 Q3, ranked #50 of 50.

· Politician BEST — appeared in 10 of the last 20 quarterly lists; latest 2026 Q1, ranked #32 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together1070.0%+4.7%+3.5%+1.2%
Share count tripled (3x)10.0%-6.1%-2.5%-3.6%
Heavy exit — 3+ tracked funds sold out together1100.0%+9.6%+5.6%+4.0%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold AMGN — ranked by lift, the co-holding pattern described in Methodology: ISHARES RUSSELL 2000 ETF (IWM) · TARGET CORP (TGT) · GILEAD SCIENCES, INC. (GILD) · ISHARES RUSSELL 1000 GROWTH (IWF) · L3HARRIS TECHNOLOGIES, INC. /DE/ (LHX) · 3M CO (MMM) · VANGUARD FTSE EMERGING MARKE (VWO) · INTERNATIONAL BUSINESS MACHINES CORP (IBM).

Filings audit: every filing lens on AMGEN INC (AMGN), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Nov 3, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 27, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain OfficersSEC filing
Aug 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

ISHARES RUSSELL 2000 ETF (IWM) · Filings audit: every filing lens on AMGEN INC (AMGN), scored · Practice timing on AMGN

One email a week: the week’s new filings and research. Subscribe free

← AMG  ·  AMH →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.